Transcarent
PrivateLast Round
M&A
Apr 8, 2025
Est. Valuation
$2.2B
Total Funding Raised
$424M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Transcarent is a healthtech company that provides a consumer-directed health and care platform for employees of self-insured employers and their families.
Sector
Healthcare & Life Sciences
Verticals
Telemedicine, Patient Engagement, Healthcare Analytics, NLP & Conversational AI, Revenue Cycle
Business Model
B2B2C
Customer Profile
Revenue Share, Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Transcarent Comparables
Compare Transcarent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Included Health | 86% | |
| Garner Health | 85% | |
| Quantum Health | 85% |
Transcarent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 8, 2025 | ||||
| Series D | May 2, 2024 | ||||
| Series C | Jan 11, 2022 | ||||
| Series B | Jun 10, 2021 | ||||
| Series A | Oct 22, 2020 |
Key People
Founding team and executive leadership
Transcarent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series D, Series C |
| GreatPoint Ventures | Series C, Series B |
| Geodesic Capital | Series D |
| Threshold Ventures | Series C, Series B, Series D |
| Ally Bridge Group | Series C, Series D |
| M13 | Series C, Series B |
| GreatPoint Ventures | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 31, 2026
Open roles increased to 1,690, 202% of headcount.
- Jul 15, 2026
Grew 16% QoQ, from 723 to 836 employees.
Recent news
Latest coverage and updates
- launchesAug 27, 2026
Transcarent launched bundled payment model for cancer therapies on Aug 25th '26.
- partners_withAug 25, 2026
Transcarent partnered with Vantrishealth on Jul 1st '26.
- hiresAug 6, 2026
Transcarent hired Mike Morgan as Chief Commercial Officer on Aug 6th '26.
- partners_withJul 22, 2026
Transcarent partnered with Tendo on Jul 22nd '26.
Transcarent Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Transcarent's valuation, stock price, and market status.
Is Transcarent a public or private company?
Transcarent is a private company.
What is the current stock price of Transcarent?
Transcarent is a private company with no public stock price. No recent secondary market data is available.
How much is Transcarent worth (valuation)?
Transcarent's valuation is estimated at $2.2B based on funding round data.
Can I buy Transcarent stock?
Transcarent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Transcarent's last funding round?
Transcarent's most recent funding round was Series D on May 2, 2024.
Who are the main investors in Transcarent?
Key investors in Transcarent include Human Capital, 7wire Ventures, General Catalyst, Kinnevik.
Will Transcarent IPO soon?
No public IPO plans have been announced for Transcarent.
How can I track Transcarent secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Transcarent's secondary market activity and sign up for updates.